TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy

Transplantation

Volumn 78, Issue 8, 2004, Pages 1218-1221

  Denton, Mark D ^a,b,c   Magee, Colm ^b,c   Melter, Michael ^a,c   Dharnidharka, Vikas R ^a,c   Sayegh, Mohamed H ^a,b,c   Briscoe, David M ^a,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Chronic rejection; Endothelial cells; Transplantation

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOSPORIN A; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE;

ALLOGRAFT VASCULOPATHY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TYPE; CONTROLLED STUDY; DISEASE COURSE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HISTOPATHOLOGY; INTIMA; LYMPHOCYTE PROLIFERATION; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR DISEASE;

ABDOMEN; ANGIOGENESIS INHIBITORS; ANIMALS; CORONARY DISEASE; CYCLOHEXANES; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; MALE; RATS; RATS, INBRED F344; RATS, INBRED LEW; SESQUITERPENES; TRANSPLANTATION, HETEROTOPIC;

EID: 7044233051     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000137266.30134.02     Document Type: Article

References (20)

1. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387.
2. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96: 2069.
3. Briscoe DM, Sayegh MH. A rendezvous before rejection: where do T cells meet transplant antigens? Nat Med 2002; 8: 220.
4. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J Exp Med 1975; 141: 1084.
5. Folkman J, Brem H. Angiogenesis and inflammation. In: Gallin JI, Goldstein IM, Synderman R, eds. Inflammation: Basic principles and clinical correlates. New York, Raven Press 1992, pp 821-839.
6. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999; 99: 1726.
7. Tanaka H, Sukhova GK, Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb 1994; 14: 734.
8. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527.
9. Lemstrom KB, Krebs R, Nykanen AI, et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002; 105: 2524.
10. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 2003; 100: 4736.
11. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348. 348: 555.
12. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69: 212.
13. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004; 10: 255.
14. Adams DH, Russell ME, Hancock WW, et al. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model. Immunol Rev 1993; 134: 5.
15. Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112: 1655.
16. Turk BE, Su Z, Liu JO. Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg Med Chem 1998; 6: 1163.
17. Lazary S, Stahelin H. Immunosuppressive effect of a new antibiotic: ovalicin. Antibiot Chemother 1969; 15: 177.
18. Griffith EC, Su Z, Niwayama S, et al. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci U S A 1998; 95: 15183.
19. Koyama H, Nishizawa Y, Hosoi M, et al. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2. Circ Res 1996; 79: 757.
20. Ogata T, Kurabayashi M, Maeno T, et al. Angiogenesis inhibitor TNP-470 (AGM-1470) suppresses vascular smooth muscle cell proliferation after balloon injury in rats. J Surg Res 2003; 112: 117.